Chilton Capital Management’s Cytokinetics CYTK Stock Holding History

Chilton Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,000	Closed	-$66.1K	–	576
2025 Q2	$66.1K	Hold	2,000	–	–	﹤0.01%	307
2025 Q1	$80.4K	Hold	2,000	–	–	﹤0.01%	282
2024 Q4	$94.1K	Hold	2,000	–	–	﹤0.01%	278
2024 Q3	$106K	Hold	2,000	–	–	﹤0.01%	280
2024 Q2	$108K	Hold	2,000	–	–	﹤0.01%	280
2024 Q1	$140K	Sell	2,000 -140	-7%	-$10.8K	0.01%	266
2023 Q4	$179K	Hold	2,140	–	–	0.01%	247
2023 Q3	$63K	Hold	2,140	–	–	﹤0.01%	307
2023 Q2	$69.8K	Sell	2,140 -125	-6%	-$4.63K	﹤0.01%	303
2023 Q1	$79.7K	Buy	+2,265	New	+$92.4K	﹤0.01%	300
2022 Q3	–	Sell	-2,265	Closed	-$89K	–	301
2022 Q2	$89K	Buy	+2,265	New	+$91.2K	0.01%	274
2022 Q1	–	Sell	-2,265	Closed	-$103K	–	306
2021 Q4	$103K	Buy	+2,265	New	+$87.4K	0.01%	275

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Chilton Capital Management's CYTK Position: Q3 2025 in Review

Chilton Capital Management sold out of Cytokinetics (CYTK) in Q3 2025, closing a stake of 2,000 shares — an estimated $66.1K sold.

Chilton Capital Management first reported a position in CYTK in Q4 2021 and held it in 12 quarters. The position peaked at $179K in Q4 2023. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

Chilton Capital Management reported no remaining Cytokinetics position as of Q3 2025 after selling out during the quarter.
Chilton Capital Management sold 2,000 Cytokinetics shares in Q3 2025, an estimated $66.1K.
Chilton Capital Management first reported a position in Cytokinetics in Q4 2021 and held it in 12 quarters.
Chilton Capital Management's Cytokinetics position peaked at $179K in Q4 2023.
380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Chilton Capital Management's 13F filing for Q3 2025, filed 31 Oct 2025.